It’s time to shift to the Exosome therapy
Lilac pharma and Hokkaido university have been developing one-step reconstitution of Exosome or Exosome-like particle in vitro.
The key technology is our exclusive microfluidic device “iLiNP”.
The reconstituted Exosome will be available for the Exosome therapy (use an exosome as drug delivery vehicle). We have been suggesting the “ExIT* Process” high-throughput drug-discovery engine that enables us to get various types of drug-like (pure) exosome-inspired particles fully reconstituted in vitro (safe and low-cost).
*ExiT = Exosome-inspired Therapeutics
The reconstituted Exosome will also be useful for a standard sample of Exosome analysis and diagnostics.
We are looking for investor(s) and collaboration partner(s) regarding the technology and the business.
Related article
One-Step Production Using a Microfluidic Device of Highly Biocompatible Size-Controlled Noncationic Exosome-like Nanoparticles for RNA Delivery.
ACS Appl. Bio Mater. 2021, 4, 1783−1793.
